Q2 2025 Holdings
Filed 2025-08-14 | 48 holdings | $939.6M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Scholar Rock Hldg Corp(SRRK) | COM | 80706P103 | $139.2M | 3,929,039 | 14.8% |
| Krystal Biotech Inc(KRYS) | COM | 501147102 | $91.2M | 663,471 | 9.7% |
| Zymeworks Inc(ZYME) | COM | 98985Y108 | $52.1M | 4,150,627 | 5.5% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $49.7M | 4,375,931 | 5.3% |
| Immunome Inc(IMNM) | COM | 45257U108 | $45.3M | 4,872,225 | 4.8% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $43.3M | 4,664,791 | 4.6% |
| Nurix Therapeutics Inc(NRIX) | COM | 67080M103 | $42.5M | 3,732,888 | 4.5% |
| Livanova PLC(LIVN) | SHS | G5509L101 | $42.1M | 934,271 | 4.5% |
| ADC Therapeutics SA(ADCT) | SHS | H0036K147 | $42.0M | 15,666,731 | 4.5% |
| Akero Therapeutics Inc(AKRO) | COM | 00973Y108 | $41.3M | 774,311 | 4.4% |
| Regenxbio Inc(RGNX) | COM | 75901B107 | $39.2M | 4,775,717 | 4.2% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $35.1M | 803,289 | 3.7% |
| Beam Therapeutics Inc(BEAM) | COM | 07373V105 | $24.2M | 1,423,411 | 2.6% |
| Absci Corporation(ABSI) | COM | 00091E109 | $21.2M | 8,253,316 | 2.3% |
| Neurogene Inc(NGNE) | COM | 64135M105 | $19.1M | 1,276,676 | 2.0% |
| Hinge Health Inc(HNGE) | CL A | 433313103 | $15.5M | 300,000 | 1.7% |
| 89Bio Inc(ETNBGBP) | COM | 282559103 | $15.2M | 1,545,208 | 1.6% |
| Annexon Inc(ANNX) | COM | 03589W102 | $15.1M | 6,300,644 | 1.6% |
| Fate Therapeutics Inc(FATE) | COM | 31189P102 | $14.4M | 12,872,946 | 1.5% |
| Silence Therapeutics PLC(SLN) | ADS | 82686Q101 | $12.6M | 2,164,777 | 1.3% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $10.4M | 1,448,040 | 1.1% |
| Biohaven LTD(BHVN) | COM | G1110E107 | $10.3M | 729,515 | 1.1% |
| Solid Biosciences Inc(SLDB) | COM NEW | 83422E204 | $9.3M | 1,915,926 | 1.0% |
| Boston Scientific Corp(BSX) | COM | 101137107 | $9.2M | 85,301 | 1.0% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $9.1M | 432,494 | 1.0% |
| Verve Therapeutics Inc | COM | 92539P101 | $8.3M | 740,261 | 0.9% |
| Ceribell Inc(CBLL) | COM | 15678C102 | $8.2M | 435,239 | 0.9% |
| Keros Therapeutics Inc(KROS) | COM | 492327101 | $7.4M | 552,506 | 0.8% |
| Celldex Therapeutics Inc New(CLDX) | COM NEW | 15117B202 | $7.0M | 343,026 | 0.7% |
| Amicus Therapeutics Inc(FOLD) | COM | 03152W109 | $6.8M | 1,188,998 | 0.7% |
| Nuvation BIO Inc(NUVB) | COM CL A | 67080N101 | $5.9M | 3,031,009 | 0.6% |
| Establishment Labs Hldgs Inc(ESTA) | COM | G31249108 | $5.8M | 136,495 | 0.6% |
| Prime Medicine Inc(PRME) | COM | 74168J101 | $5.1M | 2,074,350 | 0.5% |
| Rapt Therapeutics Inc(RAPT) | COM NEW | 75382E208 | $5.0M | 630,686 | 0.5% |
| Penumbra Inc(PEN) | COM | 70975L107 | $4.8M | 18,818 | 0.5% |
| Shattuck Labs Inc(STTK) | COM | 82024L103 | $4.4M | 5,539,724 | 0.5% |
| Atara Biotherapeutics Inc(ATRA) | COM NEW | 046513206 | $3.4M | 441,701 | 0.4% |
| IGM Biosciences Inc(1K0) | COM | 449585108 | $3.3M | 2,952,131 | 0.4% |
| Lava Therapeutics NV | SHS | N51517105 | $2.7M | 2,074,372 | 0.3% |
| Ventyx Biosciences Inc(VTYX) | COM | 92332V107 | $2.4M | 1,114,529 | 0.3% |
| Repare Therapeutics Inc(RPTX) | COM | 760273102 | $2.2M | 1,586,174 | 0.2% |
| Xeris Biopharma Holdings Inc(XERS) | COM | 98422E103 | $2.1M | 451,099 | 0.2% |
| Pliant Therapeutics Inc(PLRX) | COM | 729139105 | $1.9M | 1,632,577 | 0.2% |
| Invivyd Inc(IVVD) | COM | 00534A102 | $1.6M | 2,285,320 | 0.2% |
| ALX Oncology Hldgs Inc(ALXO) | COM | 00166B105 | $1.4M | 3,391,455 | 0.1% |
| Boundless BIO Inc(BOLD) | COM | 10170A100 | $594.9K | 589,034 | 0.1% |
| 4D Molecular Therapeutics in(FDMT) | COM | 35104E100 | $416.1K | 112,168 | 0.0% |
| Kalaris Therapeutics Inc(KLRS) | COM | 482929106 | $221.5K | 82,955 | 0.0% |